Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Phase 1 Unknown 20 enrolled Beijing Tsinghua Chang Gung Hospital

NaSingle-groupOpen-labelTreatment

Summary

The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.

Timeline

Start: 2019-11-25
Primary completion: 2021-07-31
Completion: 2021-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Summary

Timeline

Drugs

Indications